What Is Retatrutide?
Retatrutide is Eli Lilly’s experimental weight loss drug and the first triple agonist in its class. It targets three hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. Most existing drugs like Ozempic target only GLP-1. Lilly’s Zepbound targets GIP and GLP-1. Retatrutide adds glucagon — which drives additional fat burning on top of appetite suppression.
On May 21, 2026, Lilly released topline results from its Phase 3 TRIUMPH-1 clinical trial. Patients on the highest dose lost an average of 28.3% of their body weight over 80 weeks. That is the largest weight loss ever recorded in a pharmaceutical trial for obesity.
The drug is not FDA-approved and is not available by prescription anywhere in the world as of this writing. Lilly expects to file for approval as early as 2026.
Quick Takeaways
- Retatrutide (Eli Lilly) posted 28.3% average body weight loss at the highest dose in Phase 3 — highest ever recorded for any obesity medication
- It is a “triple agonist” that targets GIP + GLP-1 + glucagon receptors, unlike current GLP-1 drugs that hit one or two
- 45% of patients on the highest dose lost 30% or more of their total body weight — results comparable to gastric bypass surgery
- 11% of participants on the highest dose dropped out due to GI side effects — higher than less potent alternatives
- The drug is not yet FDA-approved and is not available anywhere as of May 2026
- For men who train: GLP-1 drugs carry a muscle-loss trade-off that retatrutide does not resolve
The Numbers Are Real — and They Are Unprecedented
Every drug class in obesity medicine has a ceiling. Semaglutide (Wegovy) peaks at around 15% body weight loss at its highest dose over 68 weeks. Tirzepatide (Zepbound) broke that ceiling at 22.5% over 72 weeks. Retatrutide at 12 mg over 80 weeks recorded 28.3% average weight loss across trial participants — and 45% of people on that dose lost 30% or more.
For context, the heaviest participants lost an average of 85 pounds over two years. That is the territory of gastric bypass surgery — a surgical procedure that reshapes your digestive anatomy. Retatrutide achieved it with a weekly injection.
The trial data also showed that 65.3% of participants on the highest dose reached a BMI below 30 kg/m² — the clinical threshold for moving from obese to overweight. These are not marginal improvements. They represent a categorical shift in what pharmaceutical intervention can achieve.
Why the Glucagon Receptor Changes Everything
Existing GLP-1 drugs work primarily through appetite suppression. They make you feel full faster, slow gastric emptying, and reduce caloric intake. Retatrutide does all of that — but the addition of glucagon receptor agonism adds a third mechanism: it signals the body to increase energy expenditure and accelerate fat oxidation independent of food intake.
Glucagon has historically been considered a counter-regulatory hormone — it raises blood sugar in response to low glucose. At the dose levels used in retatrutide, the effect is more nuanced: it promotes fat burning without the blood sugar spiking typically associated with glucagon-only compounds. That is the key insight behind the “triple G” nickname researchers have given the drug.
The practical result is a drug that cuts intake and raises output simultaneously. That is a more complete metabolic intervention than anything currently approved.
What You Actually Need to Know as Someone Who Lifts
GLP-1 drugs have a well-documented trade-off that the trial data does not fully resolve: alongside fat loss, they accelerate muscle loss. Studies on semaglutide and tirzepatide show that a meaningful portion of weight lost on these drugs is lean mass, not just fat. That matters significantly if you train seriously.
Retatrutide’s TRIUMPH-1 trial did not include body composition as a primary endpoint — it measured total body weight. What the drug does to muscle mass at clinical doses is not clearly established from the current data. Until that data exists, anyone using retatrutide (when it becomes available) without a structured resistance training and high-protein protocol is likely trading fat loss for muscle loss simultaneously.
The evidence behind strength training does not change because pharmaceutical tools have gotten stronger. If anything, the muscle-preservation argument for lifting becomes more important when your body composition is being aggressively modified by a drug. Understanding the daily habits that support physical performance matters more as the pharmaceutical baseline shifts.
The Side Effect Picture Is Not Clean
The 11% discontinuation rate for GI side effects at the highest dose is worth taking seriously. That is higher than Wegovy and Zepbound — both of which already have meaningful dropout rates from nausea and vomiting. More potent does not mean more tolerable.
Dysesthesia — abnormal skin sensations including tingling and numbness — was reported in roughly one in five participants on the highest dose in the trial. Lilly describes these episodes as generally mild and rarely leading to discontinuation, but they are a novel side effect class not commonly seen with current GLP-1 drugs.
The trial results are also topline data that has not yet gone through peer review. The full dataset, including longer-term safety follow-up, will need to survive scientific scrutiny before the FDA receives a filing — which Lilly expects to submit later in 2026.
Frequently Asked Questions
Is retatrutide better than Ozempic?
Based on Phase 3 trial data, retatrutide produces significantly greater weight loss than semaglutide (Ozempic/Wegovy). Wegovy averages around 15% weight loss at its peak dose. Retatrutide at its highest dose produced 28.3% average weight loss over 80 weeks. Whether “better” is the right word depends on your tolerance for side effects and your specific health goals — the two drugs are not directly compared in the same trial.
When will retatrutide be available?
Eli Lilly expects to file for FDA approval later in 2026. If approved on a standard timeline, availability would likely be sometime in 2027 at the earliest. It is not available by prescription anywhere in the world as of May 2026. Do not use any compound sold online claiming to be retatrutide — the drug is not approved and these products are unregulated.
What is the difference between retatrutide and tirzepatide (Zepbound)?
Tirzepatide (the active ingredient in Zepbound and Mounjaro) targets two receptors: GIP and GLP-1. Retatrutide targets three: GIP, GLP-1, and glucagon. The additional glucagon component is believed to increase fat oxidation beyond what appetite suppression alone achieves. In trial comparisons, retatrutide produced about 6 percentage points more weight loss on average than tirzepatide’s best Phase 2 results — though direct head-to-head trial data does not yet exist.
Does retatrutide cause muscle loss?
Current trial data did not include body composition as a primary endpoint, so direct muscle loss data from TRIUMPH-1 is not available yet. GLP-1 class drugs as a group are associated with lean mass loss alongside fat loss. Until retatrutide-specific body composition data is published, assuming the same muscle-loss pattern as other GLP-1 drugs is the conservative position. A structured resistance training program and adequate protein intake remain essential for anyone using these medications.
Should I wait for retatrutide instead of taking a current GLP-1 drug?
That is a medical decision you should make with a qualified healthcare provider, not from a news article. Current approved drugs (semaglutide, tirzepatide) already produce significant weight loss. Retatrutide is stronger on trial metrics but is not approved, its full safety profile is still under review, and it will not be available for at least a year. This article is for informational purposes only and is not medical advice. Consult a qualified professional before making any health decisions.
How I Know This
I have been following the GLP-1 drug class since Ozempic became mainstream conversation in 2023. I track clinical trial registries, Lilly’s investor relations announcements, and peer-reviewed pharmacology literature because this is one of the few areas where pharmaceutical science is genuinely moving faster than most people can follow. The muscle-loss concern is something I have been paying attention to specifically for the BTO audience — men who train and care about what they are losing, not just how much.
I am not a doctor or pharmacologist. The clinical data summarized here comes directly from Lilly’s public investor release and is confirmed by AJMC and CNBC coverage. This is not a recommendation to pursue pharmaceutical weight loss.
What This Actually Means Right Now
Retatrutide is not available. You cannot get it. What you can do is understand what the data says clearly — 28.3% average weight loss, the strongest Phase 3 result in obesity medicine history, with a side effect profile that is meaningfully more demanding than current alternatives.
The broader signal is this: pharmaceutical weight management is entering a different era. The tools are getting significantly more powerful. That makes everything that protects lean mass — strength training, protein intake, sleep quality — more important to understand and build into your life before pharmaceutical interventions become mainstream options.
Do not outsource your body composition to a drug you cannot yet access. Build the foundation now so that when these tools do arrive, you are using them as an accelerant, not a rescue plan.
Build the foundation before the drugs arrive
If you are serious about your body composition, start where the evidence is solid. Learn why strength training is the most evidence-backed investment you can make in your body. Understand how cardio, zone 2, and VO2 max training fit into a complete physical protocol by reading our breakdown of how much cardio you actually need. The pharmaceutical tools will come. The habits are what you build right now.
This article is for informational purposes only and is not medical advice. Consult a qualified professional before making health decisions. Retatrutide is not FDA-approved and is not available by prescription as of May 2026.